Unfortunately, the scientific efficacy of the drugs continues to be disappointingly low and a specific challenge to concentrating on EGFR with antibody therapeutics continues to be resistance caused by mutations in the downstream and effector protein
Unfortunately, the scientific efficacy of the drugs continues to be disappointingly low and a specific challenge to concentrating on EGFR with antibody therapeutics continues to be resistance caused by mutations…